Meral Beksac
@mbeksac56
Followers
2K
Following
3K
Media
606
Statuses
3K
Professor of Hematology, Ankara Liv Hosp, Istinye Univ, TurkHemSociety MM committee chair( MmGTr), EMN senior board , EBMT PCD vice chair, BMSG vice president
Ankara, Tรผrkiye
Joined November 2013
June 2022 ASCO education session: When monoclonal gammopathy is not myeloma. Open access review on SMM, AL Amyloidosis and Waldenstrรถm
6
7
72
TECVAYLIยฎ plus DARZALEX FASPROยฎ combination regimen significantly improves PFS and OS vs SOC- It will challenge some paradigms
prnewswire.com
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second...
2
11
40
Please read Dr. @majorajay's manuscript for the @TheLancetHaem Commission on AE Reporting here:
thelancet.com
As the therapeutic landscape in haematological malignancies has evolved from traditional chemotherapies to novel biological, targeted, and cellular therapies, adverse event profiles have accordingly...
Our very own @majorajay was interviewed by @RahulBanerjeeMD for The HemOnc Pulse podcast at @Blood_Cancers about patient-reported outcomes and his latest manuscript on adverse event measurement @TheLancetHaem. #lymsm cc @CUAnschutz @CUCancerCenter
0
2
8
These debates are unbiased and top level informative with a comprehensive coverage across current data
๐ข๐๐ถ๐ณ ๐ญ๐ข๐ต๐ฆ๐ด๐ต ๐ฝ๐ผ๐๐-๐๐ ๐ฆ๐ฎ๐ฌ๐ฎ๐ฑ ๐ฅ๐ผ๐๐ป๐ฑ๐๐ฎ๐ฏ๐น๐ฒ ๐๐ฒ๐ฏ๐ฎ๐๐ฒ ๐ฃ๐ฎ๐ป๐ฒ๐น: ๐ฝ๏ธ๐๐ฐ๐ธ ๐ข๐ท๐ข๐ช๐ญ๐ข๐ฃ๐ญ๐ฆ ๐ฐ๐ฏ ๐ฅ๐ฆ๐ฎ๐ข๐ฏ๐ฅ ๐๐ข๐ต๐ค๐ฉ ๐ต๐ฉ๐ฆ ๐ง๐ถ๐ญ๐ญ ๐ธ๐ฆ๐ฃ๐ช๐ฏ๐ข๐ณ ๐ง๐ฐ๐ณ ๐๐ฅ๐๐ https://t.co/8dM0d2ExuW
@Mohty_EBMT @mbeksac56 @NBahlis
@thanosdimop
0
1
12
Check out IMSound, the latest audio series from the International Myeloma Society! Each episode brings insights from top experts on crucial issues in the myeloma community. Listen, download, and share here โก๏ธ https://t.co/Z0Ehm1nm8h
0
2
4
It is so devastating to see that Pubmed will not be functional full https://t.co/1s2pycaybN๐
0
1
4
๐๐ฐ๐ช๐ฏ ๐ถ๐ด ๐ฐ๐ฏ ๐๐๐๐๐๐๐ >> ๐ง๐ต๐ฒ ๐๐๐๐ ๐ฝ๐ผ๐๐-๐๐ ๐ฆ๐ฎ๐ฌ๐ฎ๐ฑ ๐ฅ๐ผ๐๐ป๐ฑ๐๐ฎ๐ฏ๐น๐ฒ ๐๐ฒ๐ฏ๐ฎ๐๐ฒ ๐ฃ๐ฎ๐ป๐ฒ๐น ๐๏ธ๐๐ฆ๐ฑ๐ต๐ฆ๐ฎ๐ฃ๐ฆ๐ณ 23, 2025 โฒ๏ธ6๐ฑ๐ฎ ๐๐๐ ๐๐ฅ๐๐ ๐ณ๐ฆ๐จ๐ช๐ด๐ต๐ณ๐ข๐ต๐ช๐ฐ๐ฏ ๐ฃ๐ฆ๐ญ๐ฐ๐ธ๐ https://t.co/UgxSqFjgur
@Mohty_EBMT @mbeksac56 @NBahlis
1
7
12
This is a very brilliant idea of diluting the payload mafodotin concentration
#IMS25 Well, my mind is ๐คฏ - @HangQuach1 just mentioned that one partner drug for naked bela may be none other than bela-maf! Or really the other way around... Using naked bela in "BELA-MIX" study alongside bela-maf to lower #MMsm dose intensity of the latter. Fascinating!
1
1
7
#IMS25 Not bela-maf, but bela-nakedโฆ just BCMA mAb, not the ADC! @HangQuach1 presents DREAMM-20 - with bela alone, not even dex, 28% ORR and no real Gr2+ ๐๏ธ AEs (blame the โmafโ for that)! Clearly can be combined with other drugs to โฌ๏ธ ORR, just need to figure out whatโฆ
2
9
25
@Myeloma_Society Great turnout at the bone session with many questions on the lengths of bisphosphonates and imaging strategies ๐๐ปDWI-MRI !!
0
1
4
Thank you and @Myeloma_Society for the honor of co-chairing the first and most attended abstract session
1
1
8
Imaging criteria: Using Deauville criteria for PET and MY-RADS for MRI
1
2
11
What's going to be different with the new IMWG response criteria? Main changes: - FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone) - No more sCR - Bone marrow to confirm CR can be performed +/- 6 weeks from blood testing. - 24-hour urine at
3
34
69
The bispecific bonanza continues! Elra-Dara-R in MagnetisMM-6 in transplant-ineligible patients! Very high response rates, as expected and G3/4 infections of 19% at a median f/u of ~8 months. 1 death (out of 37 patients) 2/2 Candida PNA. Very high rate of IVIG ppx (>90%)! My
0
4
24
#IMS25 room 701 is going to be amazing! Learning from @HangQuach1 @RaabMarc @HiraSMian and many other oral presenters, moderated by #rafatabanour and @mbeksac56
The first #IMS25 abstract sessions start at 11:00 AM! Choose your session: ๐ Room 701 โ Abstract Session 1 ๐ Room 718 โ Abstract Session 2
1
4
30
The #IMS25 preliminary program is available! Donโt miss outโregister now! https://t.co/hwMxoOgoMc
#Myeloma #Toronto2025 ๐
1
11
16
โณWe are less than one week away from #IMS25 in Toronto! Get ready for world-class insights, valuable networking, and meaningful innovation. If you canโt join us in person, you can still take part virtually. ๐ป Register now โก๏ธ https://t.co/PRdtnkKxT9
0
11
14
Happy to be participating in the still recruting phase 3 comparing MeziVd with PVd
CONGRESS | SOHO 2025 | POSTER Paul Richardson @DanaFarber presented the updated results from the CC-92480-MM-002 trial of MeziVd (Cohorts A and D) and MeziKd (Cohort C) for the treatment of RRMM. The ORR in cohorts A and D were 75% and 85.7%, respectively. ORR with MeziKd was
0
0
3
From the second most deadly hematological cancer to โfunctional cureโ and finally the concept CURE๐๐
CONGRESS | SOHO 2025 | PRESENTATION Sundar Jagannath @TischCancer @IcahnMountSinai discussed the potential for cure in multiple myeloma; emphasizing the importance of defining cure for patients, physicians, and regulatory agencies, which should hold for both newly diagnosed
0
0
1